Epidemiology of Thyroid Cancer in Kazakhstan and in Areas Adjacent to the Former Semipalatinsk Nuclear Test Site in 2013-2023.
Gespeichert in:
| Titel: | Epidemiology of Thyroid Cancer in Kazakhstan and in Areas Adjacent to the Former Semipalatinsk Nuclear Test Site in 2013-2023. |
|---|---|
| Autoren: | Espenbetova MZ; Department of Therapy, NJSC 'Medical University of Semey', Semey, Kazhakhstan., Bidakhmetova AM; Department of Therapy, NJSC 'Medical University of Semey', Semey, Kazhakhstan., Krykpayeva AS; Department of Nursing, NJSC 'Medical University of Semey', Semey, Kazhakhstan., Yespenbetova BA; Department 'Finance' NJSC 'L.N. Gumilyov Eurasian National University', Semey, Kazhakhstan., Toleutayeva DM; Department of Epidemiology and Biostatistics, NJSC 'Medical University of Semey', Semey, Kazhakhstan., Serikbayev AS; Department of Emergency Medicine, NJSC 'Medical University of Semey', Semey, Kazhakhstan., Tukinova AR; Department of Epidemiology and Biostatistics, NJSC 'Medical University of Semey', Semey, Kazhakhstan., Uasheva LB; Endocrinologist of 'Center for Nuclear Medicine and Oncology', Semey, Kazakhstan. |
| Quelle: | Asian Pacific journal of cancer prevention : APJCP [Asian Pac J Cancer Prev] 2025 Feb 01; Vol. 26 (2), pp. 691-699. Date of Electronic Publication: 2025 Feb 01. |
| Publikationsart: | Journal Article |
| Sprache: | English |
| Info zur Zeitschrift: | Publisher: Asian Pacific Organization for Cancer Prevention Country of Publication: Thailand NLM ID: 101130625 Publication Model: Electronic Cited Medium: Internet ISSN: 2476-762X (Electronic) Linking ISSN: 15137368 NLM ISO Abbreviation: Asian Pac J Cancer Prev Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Bangkok : Asian Pacific Organization for Cancer Prevention, |
| MeSH-Schlagworte: | Thyroid Neoplasms*/epidemiology , Thyroid Neoplasms*/mortality , Thyroid Neoplasms*/pathology , Nuclear Weapons*, Humans ; Kazakhstan/epidemiology ; Female ; Male ; Incidence ; Middle Aged ; Adult ; Follow-Up Studies ; Young Adult ; Aged ; Adolescent ; Prognosis ; Survival Rate ; Child ; Child, Preschool |
| Abstract: | Objective: This study aimed to investigate the incidence and mortality of thyroid cancer (TC) in the Republic of Kazakhstan and East Kazakhstan Region, which includes the areas adjacent to the former Semipalatinsk nuclear test site over the past ten years, from 2013 to 2023. Methods: The study included information from Form No. 7 Annual "Report on Patients with Malignant Neoplasms" and "Indicators of the Oncological Service of the Republic of Kazakhstan" for the period 2013-2023. Incidence and mortality rates were calculated per 100,000 population, and data were distributed by gender, age groups, clinical stages. The study included an analysis of trends in annual epidemiological indicators, which allows us to observe fluctuations in Incidence and mortality over time. Results: Overall, Republic of Kazakstan experienced a gradual increase in incidence, beginning at 2.9 per 100,000 population in 2013, peaking at 7.2 in 2019, and ending at 5.5 in 2023. East Kazakhstan, however, showed greater fluctuation, with rates ranging from 3.2 to 4.3 per 100,000, with a notable increase in 2023 to 4.7 per 100,000 population, the highest value observed in the study period. In East Kazakhstan, mortality remained steady at 0.4 per 100,000 from 2013 to 2016, briefly increasing to 0.9 in 2018, before stabilizing at 0.4 from 2020 to 2023. Nationwide, TC mortality varied between 0.3 and 0.5 per 100,000, with a gradual decline to 0.3 per 100,000 in 2021 and 2023. Conclusion: In the areas adjacent to the former Semipalatinsk nuclear test site, significant fluctuations and peaks in morbidity are observed, which differ from the general republican indicators. |
| References: | Int J Cancer. 2015 Mar 1;136(5):1218-27. (PMID: 25041790) Endocrine. 2020 Apr;68(1):163-173. (PMID: 32002755) Trop Med Int Health. 2021 Jul;26(7):800-809. (PMID: 33837603) Ann Oncol. 2019 Dec 1;30(12):1856-1883. (PMID: 31549998) Endocr Rev. 2024 Jan 4;45(1):1-29. (PMID: 37450579) Lancet Diabetes Endocrinol. 2021 Apr;9(4):225-234. (PMID: 33662333) Asian Pac J Cancer Prev. 2019 Sep 01;20(9):2875-2880. (PMID: 31554390) J Cancer Res Ther. 2023 Jan-Mar;19(2):321-326. (PMID: 37313909) Int J Cancer. 2021 Apr 5;:. (PMID: 33818764) Int J Mol Sci. 2022 Apr 22;23(9):. (PMID: 35563021) Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1284-1297. (PMID: 35775227) |
| Contributed Indexing: | Keywords: Epidemiology; Thyroid cancer; nuclear test |
| Entry Date(s): | Date Created: 20250301 Date Completed: 20250510 Latest Revision: 20250531 |
| Update Code: | 20250531 |
| PubMed Central ID: | PMC12118041 |
| DOI: | 10.31557/APJCP.2025.26.2.691 |
| PMID: | 40022719 |
| Datenbank: | MEDLINE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Objective: This study aimed to investigate the incidence and mortality of thyroid cancer (TC) in the Republic of Kazakhstan and East Kazakhstan Region, which includes the areas adjacent to the former Semipalatinsk nuclear test site over the past ten years, from 2013 to 2023.<br />Methods: The study included information from Form No. 7 Annual "Report on Patients with Malignant Neoplasms" and "Indicators of the Oncological Service of the Republic of Kazakhstan" for the period 2013-2023. Incidence and mortality rates were calculated per 100,000 population, and data were distributed by gender, age groups, clinical stages. The study included an analysis of trends in annual epidemiological indicators, which allows us to observe fluctuations in Incidence and mortality over time.<br />Results: Overall, Republic of Kazakstan experienced a gradual increase in incidence, beginning at 2.9 per 100,000 population in 2013, peaking at 7.2 in 2019, and ending at 5.5 in 2023. East Kazakhstan, however, showed greater fluctuation, with rates ranging from 3.2 to 4.3 per 100,000, with a notable increase in 2023 to 4.7 per 100,000 population, the highest value observed in the study period. In East Kazakhstan, mortality remained steady at 0.4 per 100,000 from 2013 to 2016, briefly increasing to 0.9 in 2018, before stabilizing at 0.4 from 2020 to 2023. Nationwide, TC mortality varied between 0.3 and 0.5 per 100,000, with a gradual decline to 0.3 per 100,000 in 2021 and 2023.<br />Conclusion: In the areas adjacent to the former Semipalatinsk nuclear test site, significant fluctuations and peaks in morbidity are observed, which differ from the general republican indicators. |
|---|---|
| ISSN: | 2476-762X |
| DOI: | 10.31557/APJCP.2025.26.2.691 |